1. Home
  2. ARVN vs TMS Comparison

ARVN vs TMS Comparison

Compare ARVN & TMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$8.27

Market Cap

600.2M

Sector

Health Care

ML Signal

HOLD

Logo Teamshares Inc. Common Stock

TMS

Teamshares Inc. Common Stock

N/A

Current Price

$8.04

Market Cap

527.4M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ARVN
TMS
Founded
2015
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
600.2M
527.4M
IPO Year
2018
2025

Fundamental Metrics

Financial Performance
Metric
ARVN
TMS
Price
$8.27
$8.04
Analyst Decision
Buy
Analyst Count
19
0
Target Price
$15.05
N/A
AVG Volume (30 Days)
711.6K
111.0K
Earning Date
05-04-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
58.84
N/A
EPS
1.70
N/A
Revenue
$262,600,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$4.89
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.97
$5.04
52 Week High
$14.22
$10.10

Technical Indicators

Market Signals
Indicator
ARVN
TMS
Relative Strength Index (RSI) 38.71 58.58
Support Level $7.90 $6.93
Resistance Level $8.40 $8.00
Average True Range (ATR) 0.32 0.68
MACD -0.13 0.12
Stochastic Oscillator 11.88 86.40

Price Performance

Historical Comparison
ARVN
TMS

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

About TMS Teamshares Inc. Common Stock

Teamshares Inc is a tech-enabled company that acquires and operates small and medium-sized businesses. It uses a software platform to support activities across the acquisition lifecycle, including sourcing, evaluation, and transaction execution. After acquisition, the platform is used to integrate financial and operational data and to monitor performance across its portfolio companies. The company has two reportable segments: Small Business Acquisitions and Real Estate. The majority of revenue is derived from the Small Business Acquisitions, which includes all of the Operating Subsidiaries owned by the company.

Share on Social Networks: